Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07370597 | LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.(LUDOPATH) | recruiting | — | 110 | Jules Bordet InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer(PSMA SBRT-SIB) | recruiting | Phase 2 | 50 | Weill Medical College of Cornell University |
| 1 |
| Jan 26, 2026 |
| clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07291414 | A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | recruiting | N/A | 80 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07343349 | Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions(DAPROCA10) | recruiting | N/A | 1,016 | Rigshospitalet, DenmarkOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351461 | Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.(ANCAPRO) | recruiting | — | 432 | University Hospital, LilleOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05038332 | Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) | recruiting | Phase 2 | 136 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05264337 | Lymphedema After Urologic Surgery | recruiting | — | 400 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06406803 | The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients(DIRECT) | recruiting | N/A | 45 | Maastricht University Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05745844 | Evaluation of Neuromuscular ElectroStimulation in Addition to a Physical Activity Program(HORMES) | recruiting | N/A | 48 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05838716 | Vitamin D for Prostate Endocrine Therapy(ViPER) | recruiting | Phase 3 | 240 | University of RochesterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06830850 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 25 | Atridia Pty Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study(SCORE) | recruiting | — | 9,600 | Natera, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07344844 | Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer(SPAR) | recruiting | N/A | 100 | Clinique Sainte ClotildeOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05926102 | The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)(ProGRESS) | recruiting | N/A | 5,000 | VA Office of Research and DevelopmentFED | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04271579 | Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)(ProsTone) | recruiting | N/A | 397 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06117059 | The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance(PRECISION) | recruiting | N/A | 100 | NHS LothianOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06353321 | Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 | recruiting | — | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07129551 | Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery(NICE-PSMA) | recruiting | N/A | 102 | Martini-Klinik am UKE GmbHOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 200 | Phrontline BiopharmaINDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT07334275 | Detection of Minimal Residual Disease Post-prostatectomy(MiRaDE) | recruiting | — | 50 | Radboud University Medical CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07112599 | Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis | recruiting | — | 2,000 | Anhui Medical UniversityOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07282808 | Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer(FLAME-PC) | recruiting | N/A | 130 | Singapore General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03474913 | Upright MRI for Prostate Cancer Screening | recruiting | — | 550 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06391034 | Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | recruiting | Phase 2 | 161 | Robert Bok, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06970119 | A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 55 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07324798 | Adaptive Radiotherapy for Genitourinary Cancers(SMART-B01) | recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07319923 | Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing | recruiting | — | 3,000 | Peking University First HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07306741 | Cognitive and Fusion Prostatic Biopsy(CTB-FTB) | recruiting | N/A | 80 | Menoufia UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT04763980 | Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer | recruiting | N/A | 72 | University of California, San FranciscoOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06084338 | Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | recruiting | Phase 2 | 60 | VA Office of Research and DevelopmentFED | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07302763 | Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity(4TMPO) | recruiting | N/A | 45 | Frederic PouliotOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03492424 | Ablative Therapy in the Management of Prostate Cancer | recruiting | — | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299292 | Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | recruiting | Phase 2 | 60 | SMED Clinical ResearchOTHER | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07293585 | Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment(VORTEX) | recruiting | Phase 3 | 200 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05998278 | Personalized Optimization of Systematic Prostate Biopsy | recruiting | N/A | 330 | Fujian Medical University Union HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06200259 | Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | recruiting | N/A | 500 | Covenant Health Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03701581 | 4-aminopyridine Treatment for Nerve Injury | recruiting | Phase 2 / Phase 3 | 70 | John ElfarOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07014618 | Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer | recruiting | — | 420 | University of OklahomaOTHER | 1 | Dec 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2026source: clinicaltrials